Throughout my experience with multiple myeloma, I was humbled by the unexpected support and kindness shown to me.

Acceptance follows resolution of third-party fill/finish manufacturing issuesFDA decision expected by July 10, 2025 TARRYTOWN, N.Y., Feb. 11, ...

The PDUFA action date for an FDA decision for linvoseltamab to treat adult patients with relapsed/refractory multiple myeloma ...

Columbus’ John B Amos Cancer Center is now leading the way to administer a new cancer treatment in the Peach State.The ...

People are living longer, living better with multiple myeloma. But I think for the vast majority of people who are diagnosed, we still don't have a curative treatment for multiple myeloma, so that, to ...

In this video, Sham Mailankody, MBBS discusses the current state of the pipeline for developing multiple myeloma treatments.

The following is a summary of “Time-dependent recovery of renal impairment in patients with newly diagnosed multiple myeloma, ...

When blood cancer cells break through the bone and multiply, tumor cells become dangerously diverse and the immune response ...

The panelist discusses how for managing patients with R/R multiple myeloma, community clinicians should focus on personalized ...

Regeneron (REGN) announced that the U.S. Food and Drug Administration has accepted for review the resubmission of the Biologics License ...

Panelists discuss how to navigate and choose among multiple guideline-recommended induction regimens for patients with ...